These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21617705)

  • 1. Targeted therapy in head and neck cancer.
    Bianchini C; Ciorba A; Pelucchi S; Piva R; Pastore A
    Tumori; 2011; 97(2):137-41. PubMed ID: 21617705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
    Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.
    Rodriguez-Ramirez C; Nör JE
    Crit Rev Oncog; 2018; 23(3-4):173-187. PubMed ID: 30311573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeted therapies in head and neck cancer--an update of recent developments-.
    Goerner M; Seiwert TY; Sudhoff H
    Head Neck Oncol; 2010 Apr; 2():8. PubMed ID: 20398256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review).
    Frassanito MA; Saltarella I; Vinella A; Muzio LL; Pannone G; Fumarulo R; Vacca A; Mariggiò MA
    Oncol Rep; 2019 May; 41(5):2615-2624. PubMed ID: 30896830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New promising molecular targets in head and neck squamous cell carcinoma.
    Bauman JE; Michel LS; Chung CH
    Curr Opin Oncol; 2012 May; 24(3):235-42. PubMed ID: 22327839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
    Pollock NI; Grandis JR
    Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy for head and neck cancer: the addition of Bcl-2 inhibitors.
    Lo Russo L; Lo Muzio L
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1325-33. PubMed ID: 19943204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications.
    Schmitz S; Machiels JP
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1471-84. PubMed ID: 20836682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Shin D; Kim EH; Lee J; Roh JL
    Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in head and neck cancer: past, present and future.
    Rapidis AD; Vermorken JB; Bourhis J
    Rev Recent Clin Trials; 2008 Sep; 3(3):156-66. PubMed ID: 18782074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
    Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
    Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
    O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
    PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.